EWTX Relative Valuation
EWTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EWTX is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for EWTX's competitors is 137.02, providing a benchmark for relative valuation. Edgewise Therapeutics Inc Corp (EWTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Edgewise Therapeutics Inc (EWTX) currently overvalued or undervalued?
What is Edgewise Therapeutics Inc (EWTX) fair value?
How does EWTX's valuation metrics compare to the industry average?
What is the current P/B ratio for Edgewise Therapeutics Inc (EWTX) as of May 20 2025?
What is the current FCF Yield for Edgewise Therapeutics Inc (EWTX) as of May 20 2025?
What is the current Forward P/E ratio for Edgewise Therapeutics Inc (EWTX) as of May 20 2025?